Wockhardt to Consider Q2 FY27 Results After Q1 Profit Turnaround

Wockhardt Limited will consider its unaudited Q2 FY27 and half-year results on November 2, 2026, following a Q1 FY27 consolidated profit of ₹107 crore against a ₹108 crore loss a year earlier. The scheduled board meeting matters because the drugmaker entered FY27 with revenue rising 26% year-on-year to ₹929 crore and operating profitability strengthening.

When will Wockhardt announce its Q2 FY27 results?

Wockhardt will hold a board meeting on Monday, November 2, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company disclosed the meeting through a board-meeting intimation dated October 27.

The announcement places Wockhardt among companies scheduled to declare quarterly results on the day. Other companies listed for results include ITC, Marico, National Aluminium Company, Petronet LNG, UPL, NLC India, Container Corporation of India, Escorts Kubota, Tata Investment Corporation, Granules India, Devyani International, Amara Raja Energy & Mobility and KEC International.

The company has not provided its Q2 FY27 financial figures in the information available before the meeting. Therefore, revenue, profit, margins and any operational updates for the September quarter remain subject to the board's approval and formal disclosure. Wockhardt also said its trading window remains closed in connection with the results process.

What did Wockhardt report in Q1 FY27?

Wockhardt reported consolidated revenue from operations of ₹929 crore in the quarter ended June 30, 2026, up 26% from ₹738 crore in the corresponding quarter of the previous year. Consolidated profit after tax was ₹107 crore, compared with a loss of ₹108 crore in Q1 FY26, marking a return to profitability.

Operating profit was ₹192 crore in Q1 FY27, compared with ₹72 crore a year earlier. The quarterly earnings data showed operating profit margin at 21%, versus 10% in Q1 FY26. The company separately described EBITDA at ₹192 crore, while its earlier summary cited ₹188 crore; the quarterly financial table records operating profit of ₹192 crore.

The June-quarter result followed a consolidated profit of ₹164 crore in Q4 FY2025-26. Revenue in that preceding quarter stood at ₹965 crore, while operating profit was ₹225 crore. Compared with that quarter, Q1 FY27 revenue and profit were lower, although the year-on-year comparison reflected a substantial improvement from the loss reported in Q1 FY26.

Which businesses supported Wockhardt's first-quarter performance?

Wockhardt said its Emerging Markets, United Kingdom and Ireland businesses recorded robust revenue growth in Q1 FY27. Its India Branded Business generated ₹156 crore of revenue, rising 21% year-on-year. The company attributed this growth to branded operations, diabetic therapy, its new chemical entity EMROK and the introduction of the Regenerative Derma segment.

The company also provided updates on selected products and development programmes. Miqnaf, or nafithromycin, has been approved and launched in India. Wockhardt said the removal of a supply condition by the Drug Controller General of India enabled it to market the product to a wider patient population, after which it deployed its field force to facilitate access.

For Foviscu, also known as WCK 4282, Wockhardt said the India Phase 3 clinical trial had been completed successfully. The company had planned a New Drug Application filing in Q3 FY27. These commercial and regulatory milestones provide operating context for the company's India-focused branded business, but the available information does not quantify their contribution to Q1 revenue or profit.

How have Wockhardt's earnings changed in recent quarters?

Wockhardt's quarterly numbers show a marked recovery from the losses recorded through much of FY2024-25. Consolidated net loss was ₹108 crore in Q1 FY26, after which the company reported profits of ₹82 crore in Q2 FY26, ₹61 crore in Q3 FY26 and ₹164 crore in Q4 FY2025-26. Q1 FY27 extended the profitable run with net profit of ₹107 crore.

Revenue has also increased over the same period. Sales rose from ₹738 crore in Q1 FY26 to ₹782 crore in Q2 FY26, ₹888 crore in Q3 FY26 and ₹965 crore in Q4 FY2025-26, before reaching ₹929 crore in Q1 FY27. Operating margins expanded from 10% in Q1 FY26 to 23% in Q2 FY26 and Q4 FY2025-26, and stood at 21% in Q1 FY27.

The company said the Q1 FY27 results were reviewed by its Audit Committee and approved by the Board of Directors on August 10, 2026. The results were subject to limited review by statutory auditor MSKC & Associates LLP and prepared in accordance with Indian Accounting Standard 34. Wockhardt also disclosed that a monitoring agency report found compliant utilisation of qualified institutional placement proceeds.

What should investors assess in Wockhardt's September-quarter disclosure?

The Q2 FY27 release will show whether Wockhardt maintained the revenue growth and improved profitability reported in the June quarter. Investors can compare the September-quarter numbers with revenue of ₹929 crore, operating profit of ₹192 crore and consolidated profit of ₹107 crore in Q1 FY27, as well as with the ₹782 crore revenue and ₹82 crore profit reported in Q2 FY26.

Business updates on India branded products, international markets and product-development programmes will also be relevant because these areas were cited as drivers or potential contributors in the June-quarter disclosure. Any update on the planned Foviscu New Drug Application filing or the commercial rollout of Miqnaf would add context to Wockhardt's execution during the first half of FY27.

Wockhardt had also approved a ₹3,000 crore capital raise at its annual general meeting, according to the company information provided. The upcoming results and associated disclosures may offer investors further details on corporate actions where the company chooses to provide them. Until the formal announcement, no conclusions can be drawn on Q2 FY27 earnings or on the progress of the half-year financial performance.

Conclusion

Wockhardt enters its November 2 board meeting after a Q1 FY27 recovery in which revenue rose 26% year-on-year to ₹929 crore and the company posted ₹107 crore consolidated profit against a ₹108 crore loss a year earlier. The figures indicate materially better operating performance, supported by stronger margins and growth in the India Branded Business and certain international markets.

The immediate point to watch is the board-approved Q2 FY27 and half-year disclosure for the period ended September 30, 2026. Investors will look for comparable revenue and margin data, the status of the planned Q3 FY27 Foviscu New Drug Application filing, updates on Miqnaf's rollout, and any further information on the approved ₹3,000 crore capital raise.